Background Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell
death 1 receptor. The combination of chemotherapy and immunotherapy may have …

Adenocarcinoma of the endometrium (also known as endometrial cancer, or more broadly
as uterine cancer or carcinoma of the uterine corpus) is the most common malignancy of the …

Endometrial cancer (EC) is the most common gynecologic malignancy, with worldwide
increasing incidence and disease-associated mortality. Although most patients with EC are …

Advanced and recurrent gynecological cancers lack effective treatment and have poor
prognosis. Besides, there is urgent need for conservative treatment for fertility protection of …

Endometrial carcinoma (EC) has become one of the most common gynecological malignant
neoplasms in developed countries worldwide. Studies have shown that this may be closely …

Simple Summary Paclitaxel-based chemotherapy is the standard front-line therapy for
advanced or metastatic endometrial cancer. However, paclitaxel resistance eternally …

Endometrial cancer (ECa) is the most common female gynecologic cancer. When comparing
the two histological subtypes of endometrial cancer, Type II tumors are biologically more …

Background Fifteen percent of patients with endometrial cancer (EC) have advanced stage
disease or develop a recurrence. Progestins have been applied as systemic treatment for …

Purpose Advanced/recurrent endometrial cancer is associated with poor long-term
outcomes. Clinical studies of novel regimens are ongoing, but given that data on overall …

Background: Endometrial cancer (EC) represents a substantial economic burden for patients
in the United States. Patients with advanced or recurrent EC have a much poorer prognosis …